115 related articles for article (PubMed ID: 36502926)
21. PD-L1 expression and deficient mismatch repair in ductal adenocarcinoma of the prostate.
Lindh C; Kis L; Delahunt B; Samaratunga H; Yaxley J; Wiklund NP; Clements M; Egevad L
APMIS; 2019 Aug; 127(8):554-560. PubMed ID: 31127651
[TBL] [Abstract][Full Text] [Related]
22. PD-L1, PARP1, and MMRs as potential therapeutic biomarkers for neuroendocrine cervical cancer.
Ji X; Sui L; Song K; Lv T; Zhao H; Yao Q
Cancer Med; 2021 Jul; 10(14):4743-4751. PubMed ID: 34076351
[TBL] [Abstract][Full Text] [Related]
23. Dedifferentiated Endometrial Carcinoma Could be A Target for Immune Checkpoint Inhibitors (Anti PD-1/PD-L1 Antibodies).
Ono R; Nakayama K; Nakamura K; Yamashita H; Ishibashi T; Ishikawa M; Minamoto T; Razia S; Ishikawa N; Otsuki Y; Nakayama S; Onuma H; Kurioka H; Kyo S
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370215
[TBL] [Abstract][Full Text] [Related]
24. High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features.
Liu X; Choi MG; Kim K; Kim KM; Kim ST; Park SH; Cristescu R; Peter S; Lee J
Pathol Res Pract; 2020 Apr; 216(4):152881. PubMed ID: 32089413
[TBL] [Abstract][Full Text] [Related]
25. Non-small cell lung carcinomas with a minor sarcomatoid component and pleomorphic carcinomas are associated with high expression of programmed death ligand 1.
Tancoš V; Farkašová A; Kviatkovská Z; Grendár M; Líšková A; Huťka Z; Plank L
Pathol Res Pract; 2020 Dec; 216(12):153238. PubMed ID: 33059241
[TBL] [Abstract][Full Text] [Related]
26. Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium.
Willis BC; Sloan EA; Atkins KA; Stoler MH; Mills AM
Mod Pathol; 2017 Nov; 30(11):1622-1632. PubMed ID: 28752845
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas.
Inaguma S; Lasota J; Wang Z; Felisiak-Golabek A; Ikeda H; Miettinen M
Mod Pathol; 2017 Feb; 30(2):278-285. PubMed ID: 27813511
[TBL] [Abstract][Full Text] [Related]
28. Gastric Carcinomas With Lymphoid Stroma: An Evaluation of the Histopathologic and Molecular Features.
Hissong E; Ramrattan G; Zhang P; Zhou XK; Young G; Klimstra DS; Shia J; Fernandes H; Yantiss RK
Am J Surg Pathol; 2018 Apr; 42(4):453-462. PubMed ID: 29438172
[TBL] [Abstract][Full Text] [Related]
29. BAT26 Only Microsatellite Instability with High Tumor Mutation Burden-A Rare Entity Associated with PTEN Protein Loss and High PD-L1 Expression.
Kang SY; Kim DG; Kim KM
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142641
[TBL] [Abstract][Full Text] [Related]
30. Correlation of PD-L1 expression with immunohistochemically determined molecular profile in endometrial carcinomas.
Kir G; Soylemez T; Olgun ZC; Aydin A; McCluggage WG
Virchows Arch; 2020 Dec; 477(6):845-856. PubMed ID: 32594230
[TBL] [Abstract][Full Text] [Related]
31. Association Between Programmed Death-Ligand 1 Expression and Clinicopathological Characteristics, Structural Recurrence, and Biochemical Recurrence/Persistent Disease in Medullary Thyroid Carcinoma.
Shi X; Yu PC; Lei BW; Li CW; Zhang Y; Tan LC; Shi RL; Wang J; Ma B; Xu WB; Wang X; Hu JQ; Huang NS; Wei WJ; Wang Y; Chen TZ; Wang YL; Ji QH
Thyroid; 2019 Sep; 29(9):1269-1278. PubMed ID: 31328653
[No Abstract] [Full Text] [Related]
32. DNA mismatch repair deficiency in breast carcinoma: a pilot study of triple-negative and non-triple-negative tumors.
Wen YH; Brogi E; Zeng Z; Akram M; Catalano J; Paty PB; Norton L; Shia J
Am J Surg Pathol; 2012 Nov; 36(11):1700-8. PubMed ID: 22992699
[TBL] [Abstract][Full Text] [Related]
33. Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer.
Xiao X; Dong D; He W; Song L; Wang Q; Yue J; Xie L
Gynecol Oncol; 2018 Apr; 149(1):146-154. PubMed ID: 29496294
[TBL] [Abstract][Full Text] [Related]
34. Could Mismatch Repair Status Serve as a Biomarker for Immunotherapy in Endometrial Carcinoma?
Vagios S; Doulgeraki T; Giannikaki E; Kavoura E; Papadimitriou C; Gakiopoulou H; Pavlakis K
Anticancer Res; 2020 Mar; 40(3):1669-1676. PubMed ID: 32132073
[TBL] [Abstract][Full Text] [Related]
35. High-grade neuroendocrine carcinoma of the ampulla of vater: a clinicopathologic and immunohistochemical analysis of 14 cases.
Nassar H; Albores-Saavedra J; Klimstra DS
Am J Surg Pathol; 2005 May; 29(5):588-94. PubMed ID: 15832081
[TBL] [Abstract][Full Text] [Related]
36. Correlation of mismatch repair deficiency with clinicopathological features and programmed death-ligand 1 expression in thyroid carcinoma.
Qiao PP; Tian KS; Han LT; Ma B; Shen CK; Zhao RY; Zhang Y; Wei WJ; Chen XP
Endocrine; 2022 Jun; 76(3):660-670. PubMed ID: 35366156
[TBL] [Abstract][Full Text] [Related]
37. Programmed cell death protein 1/programmed death ligand 1 but not HER2 is a potential therapeutic target in gastric neuroendocrine carcinoma.
Yamashita S; Abe H; Kunita A; Yamashita H; Seto Y; Ushiku T
Histopathology; 2021 Feb; 78(3):381-391. PubMed ID: 32767778
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2.
Chu PG; Schwarz RE; Lau SK; Yen Y; Weiss LM
Am J Surg Pathol; 2005 Mar; 29(3):359-67. PubMed ID: 15725805
[TBL] [Abstract][Full Text] [Related]
39. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.
Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B
Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of Epstein-Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer.
Shi J; Yang X; Wang X; Luo Y; Zhou W; Luo H; Bianba Z; Nima Z; Wang Q; Wang H; Liao R; Ciren Q; Li M; Pang J
Biomed Res Int; 2022; 2022():2684065. PubMed ID: 35734348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
